Vascular endothelial growth factor and angiogenesis
ANN Hoeben, B Landuyt, MS Highley, H Wildiers… - Pharmacological …, 2004 - ASPET
Angiogenesis is a hallmark of wound healing, the menstrual cycle, cancer, and various
ischemic and inflammatory diseases. A rich variety of pro-and antiangiogenic molecules …
ischemic and inflammatory diseases. A rich variety of pro-and antiangiogenic molecules …
[HTML][HTML] International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer
H Wildiers, P Heeren, M Puts, E Topinkova… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
Purpose To update the International Society of Geriatric Oncology (SIOG) 2005
recommendations on geriatric assessment (GA) in older patients with cancer. Methods SIOG …
recommendations on geriatric assessment (GA) in older patients with cancer. Methods SIOG …
[HTML][HTML] Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations
Based on a systematic literature review, the screening tools task force of SIOG states that
screening tools do not replace geriatric assessment in older cancer patients. However, in a …
screening tools do not replace geriatric assessment in older cancer patients. However, in a …
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
Immune-checkpoint blockade (ICB) combined with neoadjuvant chemotherapy improves
pathological complete response in breast cancer. To understand why only a subset of …
pathological complete response in breast cancer. To understand why only a subset of …
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies
…, A Smeets, P Neven, H Wildiers… - Journal of the …, 2011 - academic.oup.com
Background Previous studies have suggested that breast cancer risk factors are associated
with estrogen receptor (ER) and progesterone receptor (PR) expression status of the tumors …
with estrogen receptor (ER) and progesterone receptor (PR) expression status of the tumors …
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
…, RN Hoover, D Lambrechts, P Neven, H Wildiers… - Nature …, 2015 - nature.com
Genome-wide association studies (GWAS) and large-scale replication studies have
identified common variants in 79 loci associated with breast cancer, explaining∼ 14% of the …
identified common variants in 79 loci associated with breast cancer, explaining∼ 14% of the …
[HTML][HTML] Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens …
…, YM Yeh, HT Chang, T Yau, H Wildiers… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
METHODS Patients, including those with stable, asymptomatic CNS disease, were randomly
assigned 1: 1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m 2 twice a …
assigned 1: 1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m 2 twice a …
Prediction of breast cancer risk based on profiling with common genetic variants
Background: Data for multiple common susceptibility alleles for breast cancer may be
combined to identify women at different levels of breast cancer risk. Such stratification could …
combined to identify women at different levels of breast cancer risk. Such stratification could …
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
…, HS Rugo, J Cortés, V Diéras, D Patt, H Wildiers… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: The phase II MONARCH 1 study was designed to evaluate the single-
agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 …
agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 …
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 …
…, M Smitt, R Yu, ACF Leung, H Wildiers - The Lancet …, 2014 - thelancet.com
Background Patients with progressive disease after two or more HER2-directed regimens for
recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to …
recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to …